Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 12/20 | 0.49 |
| ▸ | BIRC3 | Q13489 | 6/20 | 0.49 |
| ▸ | BIRC2 | Q13490 | 12/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26267832 | 1.00 | XIAP (0.49) | XIAPBIRC3BIRC2 | |
| SCHEMBL13574385 | 0.97 | XIAP (0.48) | XIAPBIRC3BIRC2 | |
| SCHEMBL28911875 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL21175408 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL3507780 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL15065057 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL15093340 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL17457819 | 0.85 | XIAP (0.50) | XIAPBIRC3BIRC2 | |
| SCHEMBL15064278 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 | |
| SCHEMBL15065055 | 0.85 | BIRC2 (0.53) | XIAPBIRC3BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | IGM BIOSCIENCES, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230056604-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-02-23 | — | — | US | disclosed |
| US-20200376035-A1 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | UNIV PENNSYLVANIA (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2009155709-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200376035-A1 | METHODS AND COMPOSITIONS COMPRISING CART AND A SMAC MIMETIC | CD47, HAVCR2, MICA | XIAP 90/4885BIRC3 36/4885BIRC2 33/4885 |
| US-20230056604-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, MET, ERBB2 | XIAP 936/4885BIRC3 720/4885BIRC2 582/4885 |
| US-20230174660-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CANCER THERAPY FOR TREATING CANCER | MCL1, BID, BAD | XIAP 20/4885BIRC3 24/4885BIRC2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.